Sitagliptin Approved As Add-on To Insulin
Links shared publicly online about this topic.
- 1,584total visits
Sitagliptin Approved As Add-on To Insulin
View full resource at medicalnewstoday.com
Tags: Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Insulin, Type 2 Diabetes, Glucophage, Januvia
Most Recently Shared on November 22, 2009 at 1:58 pm By:
Sitagliptin Approved As Add-on To Insulin: Sitagliptin (known as Januvia) has been approved by the European Com.. http://bit.ly/4QO9NZ
Byetta Approved as Lantus Add-On :: Diabetes Self-Management
diabetesselfmanagement.com — “On October 19, the US Food and Drug Administration (FDA) approved the Type 2 diabetes medicine Byetta (exenatide) as an add-on treatment to Lantus (insulin glargine) in people who have not achieved blood glucose control with Lantus, diet, and exercise alone...” View full resource at diabetesselfmanagement.com
Most Recently Shared on November 4, 2011 at 3:28 pm By:
Diabetes Self-Mgmt Health Site
#diabetes Byetta has been approved by the FDA as an add-on to Lantus: http://t.co/bu1TmT5z
FDA approves exenatide for use with insulin glargine
endocrinetoday.com — “The FDA has approved the use of exenatide as an add-on therapy to insulin glargine, with or without metformin or thiazolidinedione, in conjuncti” View full resource at endocrinetoday.com
Most Recently Shared on October 20, 2011 at 9:08 pm By:
#FDA approves exenatide for use with #insulin glargine http://t.co/RenCcpSr
Medical News: FDA Okays Byetta Plus Insulin Glargine - in Public Health & Policy, FDA General from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA has approved a new indication for the type 2 diabetes drug exenatide (Byetta) as an add-on therapy with insulin glargine, diet, and exercise for adult patients.” View full resource at medpagetoday.com
Most Recently Shared on October 20, 2011 at 6:35 pm By:
FDA okays Byetta plus insulin glargine: http://t.co/SjJfiocG
New Indication for Exenatide : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on October 20, 2011 at 2:18 pm By:
Bob Finn - Medical News Net Health News
FDA: Exenatide (Byetta) approved for adults with type 2 diabetes as an add-on therapy to insulin glargine. http://t.co/DKg62KJu
Abstract | Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: three case reports
jmedicalcasereports.com — “Abstract | Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: three case reports” View full resource at jmedicalcasereports.com
Most Recently Shared on April 12, 2011 at 3:00 pm By:
JMedCaseReports Medical Journal
Highly accessed #JMCR " Sitagliptin is effective and safe as add-on to insulin in patients with insulin deficiency" http://ow.ly/4yk60
Merck Receives Positive CHMP Opinion For JANUVIA(R) (sitagliptin) And JANUMET(R) (sitagliptin/metformin) As Add-On To Insulin In The European Union
medicalnewstoday.com — “Merck & co., inc., which operates in many countries as merck sharp & dohme (msd), has received a positive opinion from the european medicines agency's (emea) committee for medicinal products for h” View full resource at medicalnewstoday.com
Most Recently Shared on September 28, 2009 at 2:08 pm By:
Merck Receives Positive CHMP Opinion For JANUVIA(R) (sitagliptin) And JANUMET(R) (sitagliptin/metformin) As Add.. http://bit.ly/kuFvK
Januvia & Janumet tablets use as "add-on to insulin for the treatment of type 2 diabetes" in European Union - TuDiabetes
tudiabetes.com — “The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) is recommending Merck & Co., Inc.'s Januvia and Janumet tablets use as add-on to insulin for the treatment of type 2 diabetes. If adopted by the European Commission, sitagliptin will be the only diabetes treatment in the DPP-4 inhibitor class to have an indication for use as add-on to insulin in the European Union. (See the following link of Sept. 28th.) Also, the following link says in part t” View full resource at tudiabetes.com
Most Recently Shared on September 28, 2009 at 12:55 pm By:
Type 2 diabetes: Januvia & Janumet tablets use as "add-on to insulin for the treatment of type .. http://bit.ly/mbEpx
Medical News: FDA Approves New DPP-4 Drug for Type 2 Diabetes - in Product Alert, Prescriptions from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA today approved saxagliptin (Onglyza) for type 2 diabetes treatment, making it the first gliptin-class competitor for sitagliptin (Januvia).” View full resource at medpagetoday.com
Most Recently Shared on July 31, 2009 at 10:36 pm By:
FDA Approves New DPP-4 Drug for Type 2 Diabetes http://ow.ly/15Jspd
Advertisement
